# CBT4CBT for Office Based Buprenorphine

> **NCT03580902** · PHASE1,PHASE2 · COMPLETED · sponsor: **CBT4CBT, LLC** · enrollment: 51 (actual)

## Conditions studied

- Opioid-use Disorder

## Interventions

- **BEHAVIORAL:** CBT4CBT-Buprenorphine
- **DRUG:** Buprenorphine/naloxone

## Key facts

- **NCT ID:** NCT03580902
- **Lead sponsor:** CBT4CBT, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-22
- **Primary completion:** 2021-11-23
- **Final completion:** 2022-08-01
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2023-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03580902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03580902, "CBT4CBT for Office Based Buprenorphine". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03580902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*